

REMARKS

Claims 8 and 10-16 are pending in the present application. The specification has been amended to correct a readily apparent typographical error in the year of a cited PCT publication. No new matter has been added with this correction.

Restriction of the Claims

The Examiner has required election in the present application between:

Group I, claims 1-7, drawn to a composition;

Group II, claim 8, drawn to a treatment method; and

Group III, claim 9, drawn to a use of an antagonist.

**For the purpose of examination of the present application,
Applicants elect Group II, claim 8.**

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact MaryAnne Armstrong, PhD. (Reg. No. 40,069) at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any

overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By MaryAnne Armstrong
Gerald M. Murphy, Jr., #28,977

MaryAnne Armstrong, PhD., #40,069

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

GMM/MAA/csm
1110-0279P

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

The paragraph beginning on page 20, line 7, has been amended as follows:

The anti-Fas ligand antibody and the anti-Fas antibody used in the present invention may be prepared by known process, for example, by the process described in International Patent Application Publication No. WO 95/13293 and International Patent Application Publication No. WO ~~95/02290~~ 97/02290. These Publications are herein incorporated by reference.

IN THE CLAIMS:

Claims 1-7 and 9 have been canceled.

The claims have been amended as follows:

8. (Amended) A method for preventing and treating hepatic cirrhosis or bile duct disappearance syndrome wherein comprising the step of administering a Fas antagonist to a patient in need.

Claims 10-16 have been added.